Skip to main content
About Croma – Press & Downloads – Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter
IMG 25191

Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter

  • Company reports strong financial results for 2022 with 27% revenue growth in 2022 and
    significantly increased margins
  • Growth driven by launch of Letybo® and its catalytic effect on the existing portfolio as
    well as strong market growth
  • Continued market share gains, strategic mid-term revenue growth at a CAGR of 30%
    and further improvement of operating margins targeted

Downloads

Croma-Pharma reports 27% revenue growth in 2022 and targets further revenue growth in 2023 and thereafter (156 KB)
Back to top

If you are a healthcare professional (HCP), please log in to see specific information about our products.

Login

I've lost my password

Registration

* fields are required

This website uses cookies

We use cookies to personalise content, to provide social media features and to analyse our traffic. We also share information about your use of our website with our social media and analytics partners, which they may combine with other information you have provided to them or that they have collected from your use of their services. You consent to our cookies if you continue to use our website.